Business Services

By 2020, 70% of HCPs are expected to be digital natives, whose experiences with mobile, social, and digital technologies in their personal lives raise their expectations for business interactions. As more channels become available to HCPs, life sciences companies must adapt their approach to engaging with these customers.

Hear four perspectives from life sciences companies on how they are approaching multichannel engagement: 

It’s the end of an era at the National Institute of Health and Care Excellence (NICE), the UK watchdog responsible for negotiating and authorising access to therapies on the National Health Service (NHS), as its Chief Executive Sir Andrew Dillon announces that he will step down from his role at the end of March next year.

Sir Dillon originally joined the organisation in 1999 as its founding Chief Executive and has held the role since.

Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the use of bad data in getting its $2.1 million gene therapy Zolgensma approved by the FDA. While executives at Novartis subsidiary AveXis were kicked out, the US Senate demanded answers.

The British Government is calling on logistics companies to bid for a £25 million contract to run express freight containers carrying daily shipments of medicines into the UK after the Brexit deadline on 31 October.

The Department of Health and Social Care (DHSC) said the contract would form part of the UK’s contingency plans to deal with complications associated with Britain’s departure from the EU.

The AveXis executives that oversaw the marketing application for Zolgensma, the $2.1 million gene therapy at the centre of the faulty data scandal, are “no longer with the company” and “have not been involved” in any operations since early May, AveXis said.

This week’s top story covered the scandal surrounding Novartis over its covering up of faulty data from the FDA. The Swiss firm’s integrity was called into question after it waited until it’s $2.1 million gene therapy had been approved before informing the US regulator of inaccuracies in its data.